Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
04/20/2022* -- Results Q4 2021 -- 0.00 --
12/03/2021 -- Results Q3 2021 -- 0.00 --
09/22/2021 -- Results Q2 2021 -- 0.00 --
06/29/2021 -- Results Q1 2021 0.00 0.00 --
04/20/2021 -- Results Q4 2020 -- 0.00 --
12/11/2020 -- Results Q3 2020 0.00 0.00 --
09/01/2020 -- Results Q2 2020 -0.00 0.00 --
05/29/2020 -- Results Q1 2020 0.00 0.00 --
*Estimated Date/Time

Earnings

Next Report Date 04/20/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 12/03/2021
Beat/Miss Upgrade
Return Since -8.04%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.
URL https://www.akaritx.com
Investor Relations URL http://akaritx.com/investor-relations/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Apr. 20, 2022
Last Earnings Release Dec. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
-51.45%
-38.49%
-63.74%
11.46%
5.71%
-18.92%
-4.67%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-7.66%
--
--
--
--
--
9.15%
-55.31%
-26.88%
--
--
--
43.42%
-57.93%
-26.39%
-46.99%
15.97%
--
--
--
--
-59.81%
-32.27%
-41.95%
-23.70%
--
-66.42%
64.94%
-13.92%
-79.13%
349.2%
-30.43%
-22.93%
As of January 21, 2022.

Profile

Edit
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.
URL https://www.akaritx.com
Investor Relations URL http://akaritx.com/investor-relations/
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Apr. 20, 2022
Last Earnings Release Dec. 03, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits AKTX Tweets